PRESS RELEASE published on 12/09/2025 at 07:30, 6 months 15 days ago OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation OSE Immunotherapeutics unveils 2026–2028 strategic plan focusing on Tedopi's phase 3, rare indications for Lusvertikimab, subcutaneous formulation in UC, and maintaining scientific leadership Strategic Plan Scientific Leadership OSE Immunotherapeutics Tedopi Phase 3 Lusvertikimab Indications
PRESS RELEASE published on 10/16/2025 at 19:58, 8 months 8 days ago RAPPORT FINANCIER SEMESTRIEL 2025
BRIEF published on 10/15/2025 at 19:05, 8 months 9 days ago OSE Immunotherapeutics publie ses résultats financiers du premier semestre 2025 Baisse Des Revenus OSE Immunotherapeutics Dépenses De R&D Piste De Trésorerie Résultats Financiers 2025
BRIEF published on 10/15/2025 at 19:05, 8 months 9 days ago OSE Immunotherapeutics Reports 2025 First Half Financial Results Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
PRESS RELEASE published on 10/15/2025 at 19:00, 8 months 9 days ago OSE Immunotherapeutics Reports First Half 2025 Financial Results OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7% Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
PRESS RELEASE published on 10/15/2025 at 19:00, 8 months 9 days ago OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025, montrant une perte nette de 15,1 millions d'euros. Les activités sont estimées financées jusqu'au 4ème trimestre 2026 Résultats Financiers Biotechnologie Perte Nette OSE Immunotherapeutics Horizon De Trésorerie
BRIEF published on 10/09/2025 at 16:02, 8 months 15 days ago OSE Immunotherapeutics : Fin d'une action de concert entre actionnaires Actionnaires Franchissement De Seuil Capital Et Droits De Vote OSE Immunotherapeutics Pacte Résilié
BRIEF published on 10/09/2025 at 16:02, 8 months 15 days ago OSE Immunotherapeutics: End of a concerted action between shareholders Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
PRESS RELEASE published on 10/09/2025 at 15:57, 8 months 15 days ago Franchissement de seuils Fin de convention et action de concert chez OSE Immunotherapeutics suite à franchissement de seuils de M. Emile Loria, Mme Dominique Costantini, M. Alexis Peyroles, MS Medical Synergy SA et Aperana Consulting SARL OSE Immunotherapeutics Franchissement Seuils Fin Convention Action Concert Emile Loria
BRIEF published on 09/30/2025 at 19:35, 8 months 24 days ago OSE Immunotherapeutics: Reorganization of the Board of Directors Board Of Directors Biotechnology Immunotherapy OSE Immunotherapeutics Markus Cappel
Published on 06/24/2026 at 20:10, 37 minutes ago Fox River Obtains Final Order Approving Plan of Arrangement With Avenir Minerals Limited
Published on 06/24/2026 at 14:45, 6 hours 2 minutes ago Amdocs Selected by Three Scandinavia to Support Customer Engagement Transformation Across Nordic Markets
Published on 06/24/2026 at 14:00, 6 hours 47 minutes ago GameSquare and U.S. Army Partner for Soldier Showdown 8, Presented by USAA
Published on 06/24/2026 at 14:00, 6 hours 47 minutes ago Adcore Announces Voting Results from Annual Shareholders Meeting
Published on 06/24/2026 at 18:25, 2 hours 22 minutes ago Huawei Helps Global Carriers Monetize Tokens with Service-Network-Compute Integration
Published on 06/24/2026 at 18:25, 2 hours 22 minutes ago Annual General Meeting of Highlight Event and Entertainment AG
Published on 06/24/2026 at 18:05, 2 hours 42 minutes ago BOS GmbH & Co. KG: Admission of bonds to trading on the Luxembourg Stock Exchange
Published on 06/24/2026 at 19:00, 1 hour 47 minutes ago ALTAREA - Succès de l’option pour le paiement du dividende en actions : taux de souscription de 78,5 %
Published on 06/24/2026 at 18:00, 2 hours 47 minutes ago KERLINK : Assemblée générale mixte des actionnaires du 23 juin 2026 Seconde convocation le 9 juillet 2026.
Published on 06/24/2026 at 17:45, 3 hours 2 minutes ago Air Liquide poursuit son développement au Kazakhstan avec un investissement clé pour le complexe industriel de Silleno
